为何雄激素受体（AR）阳性前列腺肿瘤对恩杂鲁胺有反应？
Why ARNT Prostate Tumors Responding to Enzalutamide?
作者信息
Zhang Meng, Moreno-Rodriguez Thaidy, Quigley David A
机构信息
Helen Diller Family Comprehensive Cancer Center, University of California at San Francisco, San Francisco, California.
Department of Radiation Oncology, University of California at San Francisco, San Francisco, California.
出版信息
Cancer Discov. 2022 Sep 2;12(9):2017-2019. doi: 10.1158/2159-8290.CD-22-0702.
Prostate tumors can develop resistance to androgen receptor (AR)-targeted therapies through treatment-induced changes in transcription factor activity that promote transcriptional and morphologic features of a neuroendocrine lineage. This study identifies an unexpected role for the circadian protein ARNTL in resistance to enzalutamide, a second-generation AR-targeted therapy. See related article by Linder et al., p. 2074 (4).
前列腺肿瘤可通过治疗诱导的转录因子活性变化产生对雄激素受体（AR）靶向治疗的耐药性，这种变化会促进神经内分泌谱系的转录和形态学特征。本研究确定了昼夜节律蛋白ARNTL在对第二代AR靶向治疗药物恩杂鲁胺耐药中的意外作用。见Linder等人的相关文章，第2074页（4）。
Zotero 插件